Education
About Us
Working with TipRanks
Follow Us
Xintela AB (DE:1XT)
:1XT
1XT Stock Chart & Stats
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€20.25M
Enterprise Value€271.67M
Total Cash (Recent Filing)kr20.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
May 16, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding665,798,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5115.13
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Xintela AB News
---
1XT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €20.25M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is May 16, 2025 which is in 20 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Feb 28, 2025. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xintela AB have?
Xintela AB has 665,798,030 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
---
Company Description
Xintela AB
Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.
---
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Ascelia Pharma AB
―
NextCell Pharma AB
―
Immunicum AB
―
---